EYEGEN Announces NMPA Approval of World’s First Cross-linked Polyisobutylene Intraocular Lens

Click on the "blue words" above to follow more exciting content.

September 29On [Date], the National Medical Products Administration announced that Eyedeal Medical Technology Company Limited, based in Xi'an, had independently developed an innovative medical device.Cross-linked Polyisobutylene AsphericIntraocular Lens,Officially approved. This marks the global ophthalmology industryThe first new material artificial lens in 30 years has arrived.

Yuansheng Ventures led the B-round financing of Eyedea in April 2023.

This product is a single-piece posterior chamber intraocular lens, foldable, dualC-Loop. The main body and support loops of the intraocular lens are made of hydrophobic cross-linked polyisobutylene material, with added UV absorber. Diopter rangeFor+0.5 D to +34.0 D. The intraocular lens has a monofocal, aspherical optical design. This product is suitable for vision correction in aphakic eyes after cataract extraction surgery in adults.Especially, this product is the world's first to adopt cross-linked polyisobutylene material, featuring a high refractive index (1.52) and a high Abbe number (50). With a 6.5 mm large optical surface design, it can be implanted through a micro incision ≤2.0 millimeters, offering cataract patients around the world an even more ideal visual experience.

Cross-linked Polyisobutylene Intraocular Lens

The global invention patent for cross-linked polyisobutylene material is exclusively owned by Eyedeal Medical Technology Company Limited. The intraocular lens project has been selected for China's "National Key R&D Program," the National Medical Products Administration’s “Special Review Procedure for Innovative Medical Devices,” and the list of awardees for the Ministry of Industry and Information Technology and the National Medical Products Administration's "Biomedical Materials Innovation Task (Second Batch)." The implementation of this innovative achievement will promote technological advancement in China's ophthalmic medical industry and an entirely new upgrade of related industrial chains.Accelerate the transformation of more innovative materials and medical devices, and assist"Healthy China" Strategy Implementation.

About Eyedea

Eyedeal Medical Technology Company Limited was established in 2015 and is a high-tech enterprise focused on the research, development, and production of ophthalmic medical devices. Eyedea is the world's only company with two hydrophobic material platforms for intraocular lenses and is also conducting R&D and product development in other major ophthalmic disease treatments. Eyedeal’s achievements in innovative materials and production processes are particularly outstanding, which will become the driving force for further development and realization of economic benefits and social significance. The company’s core team is composed of top global professionals specializing in material research and development, optical design, clinical practice, and production. Currently, the company has established in-depth cooperative relationships with multiple hospitals, committing itself to contributing to human visual health.

END

Yuansheng VenturesIs an investment institution focused on the early and growth-stage healthcare sector, based in Suzhou bioBAY with a global reach. It has already completed investments in over 200 outstanding enterprises in the life sciences and health field, covering innovative drug development, medical devices, in vitro diagnostics, precision medicine, as well asFuture Medical TechnologyIn four major directions, substantial investment returns have been achieved, with 20 enterprises already listed on capital markets such as the Hong Kong Stock Exchange and the Sci-Tech Innovation Board. OrbiMed has been repeatedly ranked among the Top 10 venture capital funds in China's healthcare sector and recognized as one of the most active healthcare investment institutions in China. With a team of seasoned professional investors and a world-class scientific advisory board, OrbiMed possesses extensive experience in entrepreneurship, venture capital, and corporate operations in industries like biopharmaceuticals. Leveraging professionalism, dedication, and abundant industry resources, we are committed to becoming one of the most successful healthcare and pharmaceutical venture capital funds in China.